

## MEDIA ALERT

The EuroEyes logo consists of the word "EuroEyes" in a white, sans-serif font, centered within a solid blue rectangular background.

**EuroEyes International Eye Clinic Limited**

德視佳國際眼科有限公司

**(Stock Code: 1846.HK)**

### **EuroEyes Founder Increases Shareholdings; Confident in Company's 2022 2H Performance**

Hong Kong, 11 November 2022 – Dr. med. Jørn S. Jørgensen, Founder, Chairman and CEO of [EuroEyes International Eye Clinic Limited](#) (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, HKEX: 1846), a leading global vision correction service provider, has purchased an additional of approximately HK\$3,055,038 worth of the Company's shares in October. The move reflects his confidence in a strong rebound in business for the second half of 2022 and the long-term prospect of the Group.

Based on the confidence in the Group's long-term investment value, **Dr. Jørgensen** increased his shareholdings with several purchases in October on EuroEyes shares. From 1 January 2022 to 31 October 2022, **Dr. Jørgensen** purchased a total of 2,158,000 EuroEyes shares at an average price of approximately HK\$5.5668 per share. After the purchase, he holds a total of 53.99% of the Group's shares. Since January 2022, he has been a buyer who purchases from the market for the amount of approximately HK\$11,929,622 worth of EuroEyes shares as of 31 October 2022.

EuroEyes stated in its 2022 Interim Results announcement that business is returning to pre-COVID levels as the strict COVID control measures eased in China and patients in Europe resume their bookings. The Group also expects the newly opened and soon-to-open clinics and consultation centres to contribute to the Group's business performance for the remainder of the year and beyond.

**Dr. Jørgensen** said, “EuroEyes remains committed to growing sustainably. We are focused on the long term, and will continue to invest in our clinics, technology, and people to bring our world-class ophthalmology services to the growing number of patients globally. The business strategy we have set puts us in a unique growth trajectory – we operate in a niche, high end market where our services are essential to a target segment with higher spending power, and our far-reaching global presence helps diversify our business returns and risks, generating sustainable growth for the Group that will bring exceptional value to our shareholders. I am confident in our business performance going forward, and I expect to increase my shareholdings in our company in the future.”

Recently, EuroEyes signed a [medical equipment supplier agreement](#) with Carl Zeiss AG that extends their cooperation for another four years. This will ensure the stable supply of refractive surgery goods and equipment for the Group, while at the same time enable EuroEyes to further optimise its cost control measures and equip its clinics globally with state-of-the-art technologies.

###

#### **About EuroEyes International Eye Clinic Limited (1846.HK)**

EuroEyes was established in 1993 and is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and over 25 years of experience with individualised

customer care. EuroEyes is one of the few eye clinic groups with a far-reaching geographical coverage, with operations in Germany, Denmark, the PRC and the United Kingdom. The Group's vision correction services include (i) refractive laser surgery (which includes ReLEx smile and Femto LASIK); (ii) phakic lens (ICL) surgery; (iii) lens exchange surgery (which includes the monofocal and trifocal lens exchange surgery) and (iv) others (which include PRK/LASEK and ICRS implantation). For more information, please visit [www.euroeyes.hk](http://www.euroeyes.hk).

**For more information, please contact:**

**Hume Brophy Communications** – Jane Hung / Connie Chan, [euroeyeshk@humbrophy.com](mailto:euroeyeshk@humbrophy.com)